AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Capital Reinvestment Ratio
Latest as of December 2024:
0.39x
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Capital Reinvestment Ratio of 0.39x as of December 2024, meaning it reinvests 0% of its operating cash flow (€79.67 Million) in capital expenditures (€30.79 Million). See 3FMA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.39x
Capex / Operating Cash Flow
Operating Cash Flow
€79.67 Million
EUR
Capital Expenditures
€30.79 Million
EUR
Data as of
Dec 2024
Most recent filing
AEST.MED.INT.HLD.SP.ADR/3 Capital Reinvestment Ratio (2021–2024)
This chart tracks AEST.MED.INT.HLD.SP.ADR/3's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for AEST.MED.INT.HLD.SP.ADR/3 (2021–2024)
Year-by-year Capital Reinvestment Ratio for AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2024. For live market cap and broader valuation context, see market value of AEST.MED.INT.HLD.SP.ADR/3.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.39x | €79.67 Million | €30.79 Million | ▼ -48.2% |
| 2023 | 0.75x | €74.29 Million | €55.46 Million | ▲ +14.1% |
| 2021 | 0.65x | €51.09 Million | €33.44 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow